LAVA has reported progress in clinical phase achievements by Pfizer with the drug PF-08046052, previously known as SGN-EGFRd2 or LAVA-1223.

Inborn Therapeutics: Initial Participant Treated in Early-to-Mid Stage Trial of IPH6501 for Recurrent or Resistant B-Cell Non-Hodgkin Lymphoma.

CASI Pharma Announces Encouraging Early Results for BI-1206 in Managing Persistent Forms of Non-Hodgkin’s Lymphoma in Chinese Study.

Nektar Therapeutics has launched a Phase 2b trial to assess Rezpegaldesleukin in individuals with severe forms of Alopecia Areata.

Ankyra Therapeutics has commenced dosing in its initial human trial phase, assessing the effectiveness of ANK-101, a novel anchored immunotherapy, targeting a range of solid cancers.

Novartis unveils fresh insights into Zolgensma's safety and performance, highlighting sustained and enhanced motor skills in SMA-affected children who are larger and older.

Cullinan Oncology Reveals FDA Approval for Initial Trials of Unique MICA/B Antibody, CLN-619, Targeting Advanced Multiple Myeloma Cases.

ATA3219, an off-the-shelf CAR T treatment by Atara Biotherapeutics, gets green light from the FDA for its IND submission targeting Lupus Nephritis.

UK regulators have approved Ariceum Therapeutics to initiate an early-stage trial with its innovative I-123 tagged PARP blocker for individuals experiencing repeated glioblastoma.

Jacobio Pharmaceuticals Secures U.S. Go-Ahead for Experimental P53 Y220C Stimulant JAB-30300 under Investigational New Drug Status.

Innovent Reveals Initial Subject Receives Dose in Australian Phase 1 Trial for IBI3002 (a dual-action antibody targeting IL-4Rα and TSLP).

Biocon Biologics, a fully owned arm of Biocon Ltd and a global player in biosimilars, announced today a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson.